Amelie Franken, Michel Bila, Aurelie Mechels, Sam Kint, Jeroen Van Dessel, Valentina Pomella, Sebastiaan Vanuytven, Gino Philips, Orian Bricard, Jieyi Xiong, Bram Boeckx, Sigrid Hatse, Thomas Van Brussel, Rogier Schepers, Cedric Van Aerde, Sarah Geurs, Vincent Vandecaveye, Esther Hauben, Vincent Vander Poorten, Sara Verbandt, Katy Vandereyken, Junbin Qian, Sabine Tejpar, Thierry Voet, Paul M Clement, Diether Lambrechts
Cancer patients often receive a combination of antibodies targeting programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA4). We conducted a window-of-opportunity study in head and neck squamous cell carcinoma (HNSCC) to examine the contribution of anti-CTLA4 to anti-PD-L1 therapy. Single-cell profiling of on- versus pre-treatment biopsies identified T cell expansion as an early response marker. In tumors, anti-PD-L1 triggered the expansion of mostly CD8+ T cells, whereas combination therapy expanded both CD4+ and CD8+ T cells...
March 1, 2024: Immunity